UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its anti-PD-L1 drug Imfinzi (durvalumab) has successfully met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC). The trial’s success marks a significant milestone in the treatment of this aggressive form of cancer, with no new safety signals identified for the drug.
The study will proceed to further evaluate a second experimental arm that combines Imfinzi with Imjudo (tremelimumab), a CTLA-4-targeted therapy. This additional research avenue aims to explore the potential synergistic effects of the combination treatment in fighting LS-SCLC.
As stated in the press release, Imfinzi is already approved for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). The positive results from this trial could potentially expand the drug’s indication, offering hope to patients with LS-SCLC who are in dire need of more effective treatment options.- Flcube.com
